12:00 AM
 | 
Sep 07, 1999
 |  BC Week In Review  |  Company News  |  Deals

Vertex, Hoechst Marion Roussel AG deal

The companies expanded a 1993 agreement to develop oral inhibitors of interleukin-1 beta converting enzyme (ICE). Under the expansion, HMR will receive an exclusive worldwide license to develop, manufacture and market HMR 3480/VX-740,...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >